Bevacizumab Boosts Liver Resection in RAS-Positive mCRC

(MedPage Today) — Almost four times as many patients with liver-limited, unresectable metastatic RAS-positive colorectal cancer (CRC) converted to resectable status when bevacizumab (Avastin) was added to chemotherapy, a randomized trial showed…
Read More

Leave a Reply

%d bloggers like this: